The insights generated from I-O Optimise will complement clinical trial evidence, thus providing information that is not only critical for stakeholders, but also that may not be achievable through other routes. The real-world insights generated aim to improve patient outcomes and aid in the selection of cost-effective therapies that best meet patients’ expectations.
I-O Optimise aims to generate real-world insights about the management of lung cancers* in order to:
I-O Optimise aims to deliver valuable insights that may help:
The delivery of insights began in 2017, with regular updates over the long term as the treatment landscape evolves further. Over time, it should be possible to compare different populations and healthcare systems.